GlassScriptPhysician profile
Serafin Salazar
NPI 1538167713
$6,349.90
in general payments reported to CMS, 2019-2025
34 companies · $1,139 in 2025
The $1,139 reported for 2025 was more than what 92% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,364 · 2020: $443 · 2021: $509 · 2022: $479 · 2023: $544 · 2024: $872 · 2025: $1,139.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,555.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,555.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $1,499.08 | 2019 | |
| Abbvie INC. | $605.66 | 2019-2025 | Lo Loestrin Fe, Orilissa |
| Mayne Pharma Commercial LLC | $579.27 | 2022-2025 | Nextstellis, Annovera |
| Avanos Medical | $318.51 | 2019-2024 | On-Q* Pump and Accessories |
| Hologic Sales and Service, LLC | $310.00 | 2020-2025 | Novasure, Acessa Provu System, Myosure Tissue Removal Device |
| Organon LLC | $247.40 | 2021-2024 | Nexplanon |
| Caris Mpi, INC. | $238.19 | 2025 | Mi Cancer Seek |
| Aspira Women'S Health INC | $230.17 | 2020-2024 | Ova1 |
| Merck Sharp & Dohme LLC | $188.84 | 2019-2020 | |
| Lupin INC. | $180.80 | 2019-2020 | |
| Astellas Pharma US INC | $161.47 | 2023-2025 | Veozah |
| Evofem Biosciences, INC. | $160.79 | 2021-2023 | Phexxi |
| Coopersurgical, INC. | $157.99 | 2019-2025 | Paragard T 380a, Paragard T 380a |
| Therapeuticsmd, INC. | $153.28 | 2019-2022 | |
| Pfizer INC. | $152.65 | 2021-2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exeltis, USA INC. | $137.90 | 2024-2025 | Slynd |
| Alexion Pharmaceuticals, INC. | $126.79 | 2023 | |
| Agile Therapeutics, INC. | $126.54 | 2021-2024 | Twirla |
| Glaxosmithkline, LLC. | $121.84 | 2024 | Jemperli |
| Bayer Healthcare Pharmaceuticals INC. | $116.16 | 2019-2025 | |
| Exact Sciences Corporation | $104.59 | 2023-2025 | Cologuard Collection Kit |
| Sumitomo Pharma America, INC. | $63.94 | 2023-2025 | Myfembree |
| Ethicon US, LLC | $59.34 | 2023-2025 | Ethicon, Stratafix, Evarrest |
| Biogen, INC. | $55.35 | 2025 | Zurzuvae |
| Amag Pharmaceuticals, INC. | $52.05 | 2019-2020 | |
| Baxter Healthcare | $31.11 | 2021 | |
| Smith+Nephew, INC. | $29.54 | 2024 | Pico 14 |
| Allergan, INC. | $27.51 | 2019-2020 | |
| Ascend Therapeutics US, LLC | $25.00 | 2019 | |
| Vertical Pharmaceuticals, LLC | $21.57 | 2019 | |
| Millicent US INC | $20.18 | 2025 | Femlyv |
| Zyla Life Sciences, INC. | $16.73 | 2020 | |
| Duchesnay USA Incorporated | $15.71 | 2019 | |
| Davol INC. | $13.95 | 2024 | Arista Ah Flexitip |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Serafin Salazar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.